Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 public companies in the "Health services" industry, but how does it compare to its competitors? We will compare Better Therapeutics to similar businesses based on the strength of its institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Profitability
This table compares Better Therapeutics and its competitors' net margins, return on equity and return on assets.
Get Better Therapeutics alerts:| Net Margins | Return on Equity | Return on Assets | |
| Better Therapeutics | N/A | -200.73% | -114.68% |
| Better Therapeutics Competitors | -325.87% | -676.77% | -37.31% |
Risk and Volatility
Better Therapeutics has a beta of 1.36, indicating that its share price is 36% more volatile than the S&P 500. Comparatively, Better Therapeutics' competitors have a beta of 1.19, indicating that their average share price is 19% more volatile than the S&P 500.
Earnings & Valuation
This table compares Better Therapeutics and its competitors top-line revenue, earnings per share and valuation.| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Better Therapeutics | $10,000.00 | -$40.33 million | -0.69 |
| Better Therapeutics Competitors | $1.36 billion | -$98.47 million | 35.49 |
Better Therapeutics' competitors have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional and Insider Ownership
7.5% of Better Therapeutics shares are held by institutional investors. Comparatively, 48.6% of shares of all "Health services" companies are held by institutional investors. 59.4% of Better Therapeutics shares are held by company insiders. Comparatively, 21.6% of shares of all "Health services" companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Better Therapeutics and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Better Therapeutics | 0 | 0 | 2 | 0 | 3.00 |
| Better Therapeutics Competitors | 7 | 131 | 277 | 0 | 2.65 |
Better Therapeutics currently has a consensus price target of $14.00, indicating a potential upside of 900.00%. As a group, "Health services" companies have a potential upside of 98.12%. Given Better Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Better Therapeutics is more favorable than its competitors.
Summary
Better Therapeutics beats its competitors on 8 of the 12 factors compared.
About Better Therapeutics
(Get Rating)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. Its clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. The company's lead product candidate is BT-001, an investigational PDT platform to treat type 2 diabetes. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.